Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus
Completed
Kamada, Ltd.
Phase 1/Phase 2
2011-06-01
Alpha-1 Antitrypsin (AAT), trade name (Glassia ®), is being explored in this phase I/II trial
as a potential disease modifying agent in Type 1 Diabetes Mellitus (T1DM) based on its
anti-inflammatory properties. AAT is an acute stress reactant protein that increases during
inflammation. In T1DM inflammation serves a major role in disease progression.
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Terminated
Kamada, Ltd.
Phase 2/Phase 3
2017-04-26
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on
biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in
participants with acute GvHD with lower GI involvement.
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Terminated
Baxalta now part of Shire
Phase 2/Phase 3
2017-04-26
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on
biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in
participants with acute GvHD with lower GI involvement.
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Terminated
Baxalta US Inc.
Phase 2/Phase 3
2017-04-26
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on
biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in
participants with acute GvHD with lower GI involvement.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
